{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-050415","form_type":"8-K","ticker":"PRME","cik":"0001894562","company_name":"Prime Medicine, Inc.","filed_at":"2025-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.007306+00:00","generated_at":"2026-05-16T23:09:24.362774+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Prime Medicine Q3 net loss $50.6M; cash $227M funds into 2027; AATD candidate nominated","bullets":["Net loss $50.6M vs $52.5M in Q3 2024; R&D spend $44.0M (+9% YoY) driven by license costs.","Cash and investments $227M; company expects runway into 2027 under current plans.","Nominated PM647 as AATD development candidate; IND/CTA on track for mid-2026 with clinical data in 2027.","Wilson's Disease program PM577 on track for IND/CTA in H1 2026; initial data expected in 2027.","Appointed Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer to lead strategy and partnerships."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-050415","json":"https://secwatch.observer/filing/0001628280-25-050415.json","markdown":"https://secwatch.observer/filing/0001628280-25-050415.md","text":"https://secwatch.observer/filing/0001628280-25-050415.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894562/000162828025050415/0001628280-25-050415-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894562/000162828025050415/prme-20251107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:09:24.362774+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}